[CAS NO. 359625-79-9] Roluperidone

Ships within

Stock

Price

Qty

Total

$0.00

Please click "REQUEST A QUOTE" button if you need other sizes or custom synthesis

request a quote

If there is no stock, or you need other sizes or custom synthesis, please:

PRODUCTS SPECIFICATIONS [359625-79-9]

Catalog

HY-19469

Brand

MCE

CAS

359625-79-9

DESCRIPTION [359625-79-9]

Overview

MDL	MFCD28502826
Molecular Weight	366.43
Molecular Formula	C22H23FN2O2
SMILES	O=C1N(CC2CCN(CC(C3=CC=C(F)C=C3)=O)CC2)CC4=C1C=CC=C4

For research use only. We do not sell to patients.

Summary

Roluperidone (CYR-101) is a novel cyclic amide derivative that has high equipotent affinities for 5-HT _2A and sigma-2 receptors ( K _i of 7.53 nM and 8.19 nM for 5-HT _2A and sigma-2, respectively).

IC50 & Target

5-HT _2A Receptor

7.53 nM (Ki)

Sigma-2 Receptor

8.19 nM (Ki)

In Vitro

Roluperidone (CYR-101) also shows binding affinity for α ₁ -adrenergic receptors but low or no affinity for muscarinic, cholinergic, and histaminergic receptors. Although Roluperidone (CYR-101) has no affinities for pre- or postsynaptic dopaminergic receptors, it is probable that sigma-2 receptors are implicated in the modulation of dopamine and glutamatergic pathways, as well as in calcium neuronal modulation ^[1] .

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Clinical Trial

NCT Number	Sponsor	Condition	Start Date	Phase
NCT02232529	Minerva Neurosciences	Schizophrenia	September 2014	Phase 1
NCT00861796	Cyrenaic Pharmaceuticals	Schizophrenia	March 2008	Phase 2
NCT03038646	Minerva Neurosciences	Healthy Subjects	November 30, 2016	Phase 1
NCT03397134	Minerva Neurosciences	Negative Symptoms of Schizophrenia	December 15, 2017	Phase 3
NCT03072056	Minerva Neurosciences	Healthy Subjects	January 9, 2017	Phase 1

Appearance

Solid

Shipping

Room temperature in continental US; may vary elsewhere.

Storage

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	6 months
	-20°C	1 month

Solvent & Solubility

In Vitro:

DMSO : 33.33 mg/mL ( 90.96 mM ; Need ultrasonic)

Preparing
Stock Solutions

Concentration Solvent Mass	1 mg	5 mg	10 mg

1 mM	2.7290 mL	13.6452 mL	27.2903 mL
5 mM	0.5458 mL	2.7290 mL	5.4581 mL
10 mM	0.2729 mL	1.3645 mL	2.7290 mL

* Please refer to the solubility information to select the appropriate solvent.

In Vivo:

1.

Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline

Solubility: ≥ 3 mg/mL (8.19 mM); Clear solution
2.

Add each solvent one by one: 10% DMSO >> 90% corn oil

Solubility: ≥ 3 mg/mL (8.19 mM); Clear solution
3.

Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline)

Solubility: ≥ 2.5 mg/mL (6.82 mM); Clear solution

* All of the co-solvents are available by MCE.

References

[1] Davidson M, et al. Efficacy and Safety of MIN-101: A 12-Week Randomized, Double-Blind, Placebo-Controlled Trial of a New Drug in Development for the Treatment of Negative Symptoms in Schizophrenia. Am J Psychiatry. 2017 Jul 28:appiajp201717010122.

Synonyms

1H-Isoindol-1-one, 2-[[1-[2-(4-fluorophenyl)-2-oxoethyl]-4-piperidinyl]methyl]-2,3-dihydro-

2-[[1-[2-(4-Fluorophenyl)-2-oxoethyl]-4-piperidinyl]methyl]-2,3-dihydro-1H-isoindol-1-one

CYR 101

Roluperidone

2-({1-[2-(4-fluorophenyl)-2-oxoethyl]piperidin-4-yl}methyl)-2,3-dihydro-1H-isoindol-1-one

FMI

2-((1-(2-(4-Fluorophenyl)-2-oxoethyl)piperidin-4-yl)methyl)isoindolin-1-one